fbpx

News

Lundbeckfonden Ventures News

Paris, France – 1 May 2014 ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, is pleased to announce that it has raised ?10 million in the first tranche of a Series B fund raising. The funding has been led by the...
South San Francisco, CA and Atlanta, GA- April 16, 2014 – Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures. Iconic’s lead clinical-stage program is a...
Oxford Early Results with CERAMENTT’G show no recurrence of infection, no toxicity and no renal complications.. No late wound leakage and 78 % of patients showing complete bone ingrowth at 6 months. Lund, Sweden, (PRNEWSWIRE) April 15, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation...
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation From FDA's Center for Biologics Evaluation and Research (CBER)
Boston, MA – scPharmaceuticals LLC today announced that it has entered into a strategic partnership and product development agreement with Sensile Medical Holding AG of Zug, Switzerland to develop an innovative new therapeutic option for patients with heart failure.  The terms of the agreement were not disclosed. The drug-device combination uses the Sensile SenseCore technology in...
Conference Call Today at 4:30 p.m. Eastern TimeSAN DIEGO, March 31, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced financial results for the quarter and year ended December 31, 2013. "Celladon executed on key...
SAN DIEGO, April 1, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that effective as of the close of the market on Monday, March 31, 2014, the Company was added to the Russell 2000®...
Celladon to Present at BioCentury's Future Leaders in the Biotech Industry ConferenceSAN DIEGO, March 20, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that Krisztina Zsebo, Ph.D., President and Chief Executive Officer, will present...
1 42 43 44 45 46 58

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Acacia Pharma Group plc – Issue of Equity on Exercise of Options
16. August 2019
Acacia Pharma Group PLC – Acacia Pharma Group plc: Notice of Interim Results
12. August 2019
Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
31. July 2019